Table 1.

Strategies for progression of infant chiasmatic hypothalamic glioma

Duration of 1st line treatment		n	%
Length of primary treatment	12 months	7	15
	18 months	38	81
	60 weeks	1	2
	Prolonged duration	1	2
Considering prolonged maintenance after firstline therapy	Yes	17	36
	No	30	64

Types of treatment considered	2nd line treatment at progression during carboplatin/vincristine		Progression after end of carboplatin/vincristine		3rd line treatment if not responsive or early progression
	n	%	n	%	n	%
Surgery only	–		–	–	3	6
Surgery and continue/restart carboplatin/vincristine	4	9	3	6	3	6
Surgery and other chemotherapy	23	49	15	32	20	43
Different chemotherapy	17	36	9	19	3	6
Restart carboplatin/vincristine			13	27	–
Monotherapy targeted	–		–		4	9
Targeted and other chemo	1	2	2	4	14	30
Brachytherapy	–		–		–
External beam radiotherapy	2	4	–		–
Missing			1	2
Total	47	100	47	100	47	100

Drugs applied (multiple answers allowed)
Median Range	2 1–6		2 1–8		2 1–7
Number of respondents Missing	47		46 1		47
Actinomycin D	2	4	3	6	3	6
Bevacizumab	9	20	5	11	25	53
Carboplatin	4	9	10	22	2	4
CCNU	1	2	1	2	5	11
Cisplatin	16	34	10	22	3	6
Cyclophosphamide	12	26	9	20	2	4
Etoposide	10	21	8	17	2	4
Everolimus	–		–		3	6
Ifosfamide	1	2	1	2	–	–
Imatinib mesylate	–		1	2	4	9
Irinotecan	5	11	3	6	19	40
MEK inhibitor	–		1	2	1
Methotrexate	1	2
Nilotinib	5	11	5	11	3	6
Procarbazine	2	4	2	4	6	13
Temozolomide	2	4	4	9	2	4
Thioguanine	2	4	2	4	5	11
Vinblastine	29	62	25	54	16	34
Vincristine	11	23	16	35	9	19
Other drugs			2a	4	8b	19

^aVinorelbine

^bNavelbine, fluvastatine, dacarbazine, thalidomide, celecoxib, fenofibrate